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Mas-related G-protein-coupled receptor subtype C and subtype X1 (mouse MrgprC11, rat 
MrgprC and human MrgprX1) are a novel group of receptors as promising targets of pain 
inhibitors, mainly because of their restricted expression in small diameter nociceptors within the 
peripheral nervous system. Drug screens have been conducted targeting at human MrgprX1. 
However, constrained by the species difference across Mrgprs, many drug candidates could 
activate MrgprX1 but not the rodent ones, leaving no animal model responsive to test the anti-
chronic pain effect in vivo. Our laboratory recently generated a transgenic mouse line in which we 
replaced a cluster of twelve mouse Mrgprs (including MrgprC11) with human MrgprX1. This 
valuable humanized mouse line allowed us to characterize a potent positive allosteric modulator 
of MrgprX1, ML382. Cellular studies in humanized MrgprX1 mice suggest that ML382 enhances 
the ability of bovine adrenal medulla peptide (BAM22, or BAM8–22) as the orthosteric agonist to 
inhibit N-type voltage-activated calcium current through pertussis toxin sensitive Gi/o pathway. We 
then used several behavior tests to evaluate the analgesic effect of ML382 in inflammatory pain 
and neuropathic pain animal models. We also observed that MrgprX1 expressing animals 
developed strong conditioned place preference to ML382 paired chamber comparing to saline 
paired chamber. Importantly, ML382 effectively attenuates evoked persistent and spontaneous 
pain without causing peripheral or central side effects such as itch, motor dysfunction, or being 
rewarding for the uninjured naïve animals. Our findings suggest that humanized MrgprX1 mice 
provide an essential preclinical model and that allosterically activating MrgprX1 by ML382 is a 
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CHAPTER 1: INTRODUCTION 
Persistent pain is a major health care problem and yet it is hard to manage partly 
because it requires sustained application of pain relief over the duration of the chronic pain. 
However, repetitive application of many pain treatments (e.g. systemic opioids) often decreases 
the analgesic response and the long term impact of undesired side effects (e.g. sedation, nausea, 
constipation, addiction, etc.) can further deteriorate life quality in addition to chronic pain itself 
(Portenoy, 1996; Breivik et al., 2006).  
One reason that most pain medicines produce an extensive array of side effects is the 
broad expression of drug targets (e.g. opioid receptors, cyclooxygenase-2 or COX-2, calcium 
channels, etc.) in the central and peripheral nervous system, immune pathways, cardiovascular 
system, etc. (Scholz and Woolf, 2002). Hence, a more pain-selective pharmacologic intervention 
should target at receptors that express exclusively inside the pain pathway. Especially, chronic 
pain is often primed with peripheral pathological conditions such as inflammation and nerve injury 
that sensitize nociceptors (Basbaum et al., 2009; Pope et al., 2013). It would be of great value to 
identify novel molecular targets on nociceptive sensory neurons in the trigeminal and dorsal root 
ganglia (DRG) (He et al., 2014). 
G protein-coupled receptors (GPCRs) have been very fruitful drug targets in recent years. 
One potential target is the Mas-related G-protein–coupled receptor (Mrgpr), which is a family of 
orphan GPCRs consisting of many genes in human, rat and mouse (Dong et al., 2001; Lembo et 
al., 2002; Choi and Lahn, 2003; Zhang et al., 2005; Gloriam et al., 2007). Many Mrgprs, such as 
mouse MrgprA3, MrgprC11, MrgprD, rat MrgprC and human MrgprXs, are expressed specifically 
in small-diameter afferent neurons (presumably nociceptive) and have been reported to play 
important roles in peripheral sensation (Zylka et al., 2003; Conn et al., 2009; Liu et al., 2009; 
Guan et al., 2010; Sikand et al., 2011; Liu et al., 2012; Han et al., 2013; He et al., 2014; He et al., 
2014). For example, subcutaneous chloroquine induces strong scratching behavior in mice 
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through MrgprA3 (Liu et al., 2009). Activation of MrgprC with agonists such as bovine adrenal 
medulla peptide (BAM) 8–22 and JHU58 (by intrathecal [i.th.] application) attenuates persistent 
pain in an MrgprC-dependent manner in rodents (Guan et al., 2010; He et al., 2014). 
Interestingly, Mrgpr-clusterΔ-/- mice (which have a deletion of 12 Mrgprs, including 
MrgprA3 and MrgprC11) display enhanced spontaneous pain responses in the inflammatory 
phase of formalin-induced pain (Guan et al., 2010). They also have a prolonged phase of 
mechanical hypersensitivity in the L5 sciatic chronic constriction injury model (He et al., 2014). 
Therefore, we have been interested to investigate the analgesic effect of human MrgprX1 under 
chronic pain condition for potential clinical application. However, constrained by the species 
difference across Mrgprs, many drug candidates activate MrgprX1 but not the rodent ones. The 
progress of further developing these drugs is impeded due to the lack of animal model to test the 
anti-chronic pain effect in vivo. In this article, we report the generation of a transgenic mouse line 
in which MrgprX1 gene is expressed in Mrgpr-expressing primary sensory DRG neurons.  
Rodent MrgprCs and MrgprX1 has been reported for both analgesic and pruritogenic 
effect (Liu et al., 2009; Guan et al., 2010; Sikand et al., 2011; Han et al., 2013; Jiang et al., 2013; 
He et al., 2014). To avoid inducing itch by the activation of peripherally expressed MrgprX1, we 
used the strategy of allosterically enhancing the endogenous activity of MrgprX1 at the site where 
receptor and endogenous ligand co-exist, i.e., at the central terminal (See model in Fig. 1.1). 
Mrgpr+ DRG neurons terminate both centrally at spinal cord lamina II and peripherally at skin 
(Han et al., 2013). BAM22 immunoreactivity was found in several tissues including brain and 
superficial spinal cord dorsal horn (Mizuno et al., 1980; Hollt et al., 1982; Cai et al., 2007; Solinski 
et al., 2014). Therefore, we perform our behavioral study by intrathecal application of allosteric 




Figure 1.1 The central and peripheral function of MrgprX1+ DRG neurons.  A model showing 
the functional compartmentation of MrgprX1+ DRG neurons. Peripheral activation of MrgprX1 
receptor with exogenous agonist produces action potential and generates itch sensation. In 
persistent pain condition, central activation of MrgprX1 inhibits synaptic input into spinal cord 
dorsal horn neurons to attenuate persistent pain. BAM peptide is an endogenous agonist of 





Allosteric modulators have become a popular direction in the drug discovery for GPCRs. 
It binds to the allosteric site and modulates the responsiveness of its receptor together with the 
binding of orthosteric ligand (Conn et al., 2009). It can offer high selectivity since the orthosteric 
binding sites are often conserved across a GPCR subfamily. It also allows a better temporal and 
spatial control of modulating endogenous physiological signaling due to the requirement of 
endogenous orthosteric ligand binding. Further, screening for allosteric modulators in the pool of 
small molecule compounds provides the possibility of better penetration of blood brain barrier and 
therefore multiple drug delivery methods other than intrathecal (Wen et al., 2015).  
In this study, we performed screening for allosteric modulators of MrgprX1 and got a 
candidate ML382. We also demonstrate that activation of MrgprX1 by BAM8–22 reduces 
neurotransmitter release by inhibiting N-type voltage-activated calcium current through PTX 
sensitive Gi/o pathway. MrgprX1 agonist BAM22 (endogenous) is up-regulated at spinal cord 
dorsal horn under chronic pain condition. We hypothesize that positive allosteric modulator 




CHAPTER 2: ML382 IS A CANDIDATE OF ALLOSTERIC MODULATOR OF MRGPRX1 
Introduction  
GPCRs represent the largest class of cell-surface receptors and have been implicated in 
numerous disorders (George et al., 2002). Despite almost half of all modern drugs regulate the 
activity of GPCR activity in some way, the majority of GPCRs have not successfully been targets 
by useful ligands yet (Conn et al., 2009). It is often difficult to develop ligands with high selectivity 
at specific GPCR subtypes because their orthosteric binding sites can be highly conserved 
across a GPCR subfamily; plus it is often infeasible to develop small molecule drugs for some 
GPCRs whose orthosteric binding sites are designed for peptides or proteins (Conn et al., 2009). 
Researchers therefore tried to approach with selective allosteric modulators, which bind to 
allosteric binding sites and either potentiate or inhibit the activation of the receptors by their 
endogenous orthosteric ligands (May et al., 2007). 
Developing drugs targeting at MrgprX1 has an extra fold of conundrum, that directly 
activating MrgprX1 at peripheral terminals induces itch in rodents and humans (Liu et al., 2009; 
Sikand et al., 2011). Therefore, targeting this receptor with an orthosteric activating drug is an 
unviable approach to pain relief. Allosteric ligands that bind at allosteric binding sites provide 
better specificity than orthosteric ligands alone because they require co-localization of receptor 
and orthosteric ligand to function. As long as the endogenous orthosteric ligand of MrgprX1 is 
restricted at the pain-processing central terminal of DRG neurons, the allosteric drug would 
function only there even when it is administrated systemically. 
We therefore conducted a screen of the 307000 NIH Molecular Library Small Molecule 
Repository (MLSMR) compound collection using a triple addition protocol with BAM8–22 as the 
orthosteric ligand (Assay ID: 588675) with the help of Vanderbilt Center for Neuroscience Drug 
Discovery. The flow chart of screening paradigm for positive allosteric modulator of MrgprX1 is as 




Figure 2.1 Flowchart of the screening paradigm for allosteric modulators of MrgprX1 
(adapted from Wen et al.) (2015).
•1932 hits, 0.63% Primary screen from307000 MLSMR library 
•1164 Re-tested, 149 active, 78% re-confirmation rate Medicinal Cheimstry Triage (unwanted fragments, PAINs) 
•165 compounds with no HEK293 activity Hits counter-screened against parental cells 
•29 compounds confirmed with 5-point CRC Compound tested in 5-pointed concentration-responsive curve (CRC) 





Screen using FLIPR Calcium Imaging 
HEK293 wild type cells or HEK293 cells stably expressing MrgprX1 were cultured on 
poly-D-lysine coated 96-well plate overnight. Center point confluency should be around 90%–100% 
at the time of the assays. FLIPR Calcium Assay 5 kit (Molecular Devices, Sunnyvale, CA) was 
used as free calcium ratiometric indicator. After incubating with the indicator solution for 40 min at 
37°C followed by 10 min at room temperature, the plate was loaded in the Flexstation machine. 
Each well contained 100μL solution initially and was then incubated with 50μL candidates of 
positive allosteric modulators (diluted in 1×HBSS + 20mM HEPES) or vehicle for 80 sec. Then 
50μL BAM8–22 (10nM, very low dose) or vehicle was added. Compound plates of BAM8–22 
were coated with 1% BSA (to avoid BAM8–22 sticking to the wall of the plate for 1hr prior to 
FLIPR assays. Tips were changed between each cell plate and each drug plate. Readings were 
compared between the candidates and vehicle to see whether the candidates could increase 
BAM8–22 response. [Reading = (candidate-BAM−vehicle-BAM) ÷ (vehicle-BAM−vehicle-vehicle) 
×100%]. The reading of each candidate was replicated in three wells and the promising 
candidates were repeated later again for dose response curve.  
Liquid Chromatography/Mass Spectrometry Analysis (LC/MS/MS) of ML382 in the Cerebral 
Spinal Fluid 
ML382 was analyzed via electrospray ionization (ESI) on an AB Sciex API-4000 (Foster 
City, CA) triple-quadrupole instrument that was coupled with Shimadzu LC-10AD pumps 
(Columbia, MD) and a Leap Technologies CTC PAL auto-sampler (Carrboro, NC). Analytes were 
separated by gradient elution using a Fortis C18 2.1 x 50 mm, 3.5 μm column (Fortis 
Technologies Ltd, Cheshire, UK) thermostated at 40 °C. HPLC mobile phase A was 0.1% NH4OH 
(pH unadjusted), mobile phase B was acetonitrile. The gradient started at 30% B after a 0.2 min 
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hold and was linearly increased to 90% B over 0.8 min; held at 90% B for 0.5 min and returned to 
30% B in 0.1 min followed by a re-equilibration (0.9 min). The total run time was 2.5 min and the 
HPLC flow rate was 0.5 mL/min. The source temperature was set at 500°C and mass spectral 
analyses were performed using multiple reaction monitoring (MRM) utilizing a Turbo-Ionspray® 
source in positive ionization mode (5.0 kV spray voltage). LC/MS/MS analysis was performed 
employing a TSQ QuantumULTRA that was coupled to a ThermoSurveyor LC system 
(Thermoelectron Corp., San Jose, CA) and a Leap Technologies CTC PAL auto-sampler 
(Carrboro, NC). Chromatographic separation of analytes was achieved with an Acquity BEH C18 
2.1 x 50 mm, 1.7 μm column (Waters, Taunton, MA). 
Plasma Protein Binding  
Protein binding of ML382 was determined in human, rat and mouse plasma via 
equilibrium dialysis employing Single-Use RED Plates with inserts (ThermoFisher Scientific, 
Rochester, NY). Briefly plasma (220 μL) was added to the 96 well plate containing test article (5 
μL) and mixed thoroughly. Subsequently, 200 μL of the plasma-test article mixture was 
transferred to the cis chamber (red) of the RED plate, with an accompanying 350 μL of phosphate 
buffer (25 mM, pH 7.4) in the trans chamber. The RED plate was sealed and incubated 4 h at 
37 °C with shaking. At completion, 50 μL aliquots from each chamber were diluted 1:1 (50 μL) 
with either plasma (cis) or buffer (trans) and transferred to a new 96 well plate, at which time ice-
cold acetonitrile (2 volumes) was added to extract the matrices. The plate was centrifuged (3000 
rpm, 10 min) and supernatants transferred to a new 96 well plate. The sealed plate was stored at 
-20 °C until LC/MS/MS analysis. 
Statistics  
Data are presented as mean ± s.e.m. The number of mice analyzed is represented as n. 
Statistical comparisons were conducted by two-tailed, unpaired or paired Student’s t test 
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according to experimental design. Statistical significant difference was assumed at P < 0.05. 
Experiments were replicated biologically at least three times. 
Results 
Calcium mobilization screen suggested ML382 modulates MrgprX1 
From the 29 identified “hits” mentioned in Fig. 2.1, there were four compounds from a 
sulfonamide benzamide series. Combining the activity in the calcium mobilization functional 
assay and excellent selectivity profile as observed in the PubChem Assay and PubChem Hit rate 
(Assay ID: 588675), this series was chosen for further modification toward a novel positive 
allosteric modulator of MrgprX1. Then 19 modified compounds went through further screening 
(Assay ID: 743016), yielding ML382 of the highest potency and efficacy (Wen et al., 2015). 
The dose-response studies show that 5 µM ML382 enhances the potency of BAM8–22 
on MrgprX1 by >7-fold (i.e., EC50 of BAM8–22 from 18.7 to 2.9 nM; Fig. 2.2A). However, ML382 
does not affect the Emax of BAM8–22 if the maximum concentration of BAM8–22 is used (Fig. 
2.2A). Furthermore, ML382 does not activate MrgprX1 in the absence of BAM8–22, suggesting 
ML382 itself does not has agonistic activity toward MrgprX1 (Fig. 2.2B). Pharmacological and 
selectivity profiling of ML382 were performed against the closely related MrgprX2 in HEK293 
stable cell line expressing MrgprX2 as a selectivity screen. The orthosteric agonist we used was 
proadrenomedullin amino-terminal 20 peptide, fragment 9-20 (PAMP(9-20)) (Kamohara et al., 
2005). ML382 showed no significant effect on the activation of MrgprX2 in the presence of the 










Figure 2.2 Pharmacological profile of ML382 on MrgprX1-expressing HEK293 cells. (A) 
ML382 enhances the potency of BAM8–22 on MrgprX1-expressing HEK293 cells. Dose-response 
curve of BAM8–22 in presence (red dots) or absence of ML382 (black squares) was determined 
by Ca2+ mobilization assays. The EC50 of BAM8–22 in presence of maximal amount of ML382 (5 
µM) is 2.87 ± 1.22 nM (95% confidence interval). In the absence of ML382 (black squares), the 
EC50 of BAM8–22 is 18.67 ± 1.06 nM (95% confidence interval). Inset: the chemical structure of 
ML382. (B) Dose-response curve of ML382 in the presence (red dots) and absence (black 
squares) of BAM8–22 as determined by Ca2+ mobilization assays. The EC50 value of ML382 in 
the presence of submaximal amounts of BAM8–22 (10 nm) is 190 nm. In the absence of BAM8–
22 (black squares), ML382 itself does not activate MrgprX1. (C) ML382 has no effect on 
MrgprX2-expressing HEK293 cells. Dose-response curve of PAMP in presence (red circles) or 
absence of ML382 (black squares) was determined by Ca2+ mobilization assay. The EC50 of 
PAMP in presence of 5 μM ML382 is 316.12 ± 17.8 nM (95% confidence interval). In the absence 
of ML382, the EC50 of BAM8–22 is 211.86 ± 51.98 nM (95% confidence interval). RFU: relative 
fluorescence units; values are the mean ± SEM of three repeat experiments, and data points are 




In addition, ML382 was evaluated using the Eurofins Lead Profiling Screen, which is a 
binding assay panel of 68 GPCRs, ion channels, and transporters screened at 10 µM (Eurofins 
Scientific: http://www.eurofins.com/en.aspx accessed in August 2014). ML382 did not inhibit 67 of 
the 68 targets assayed (inhibition of radioligand binding >50% at 10 µM); the only target that was 
considered active was serotonin (5-hydroxytryptamine) 5HT2B, which showed 63% inhibition at 10 
µM (See materials from Eurofins attached below). Overall, ML382 displayed a very favorable 












In vivo concentration in cerebral spinal fluid and plasma stability of ML382 
In order to quantify the concentration of ML382 exposed at spinal cord as a reference for 
further cellular studies, we dissected the spinal cords out 30 min after intrathecally injecting 10 μL 
of 250 μM ML382 or 10 μL saline as control and incubated the spinal cord in 500 μL oxygen 
saturated aCSF (artificial cerebral spinal fluid) at 37°C for an hour. The amount of ML382 in the 
aCSF was detected using liquid chromatography/mass spectrometry analysis. The amount of 
ML382 detected is 4.48 ± 2.24 ng/mL (average ± s.e.m., n = 3). Assuming the 10 μL drug is 
diluted 50 times in the 500 μL aCSF (since the amount of endogenous cerebral spinal fluid is 
minimal), the concentration is 1.08 ± 0.68 μM. The actual concentration at lumbar region in vivo 
could be higher since the intrathecal injection is between lumbar 5 and sacral 1. The amount of 
ML382 in the mice which were intrathecally injected with saline was below the limit of 
quantification. We also measured the level of ML382 over time in plasma and found that it is 
relatively stable in human and rat plasma but not in mouse plasma (Table 2.1). 
Time Mouse Rat Human 
0 hr 100% 100% 100% 
1 hr 98.47% 102% 103% 
4 hr 69.15% 91% 100% 
 
Table 2.1 Pharmacokinetic study of ML382. ML382 was incubated with mouse, rat or human 
plasma for 0 hr, 1 hr, or 4 hr and then quantified by LC/MC/MC analysis. ML382 was unstable in 




In summary, we developed ML382 as a potent and selective allosteric modulator of 
MrgprX1 receptor using calcium mobilization functional assay in HEK293 cells that express this 
receptor stably. This is the first positive allosteric modulator reported for MrgprX1 (Wen et al., 
2015). In the presence of the known ligand BAM8–22, ML382 has an EC50 value of 190 nm with 
an Emax value of 148% of the effect caused by BAM8–22 alone. It is inactive against the closely 
related MrgprX2 and against a group of selected receptors from the Eurofins panel. In addition, 
ML382 was profiled in pharmacokinetic assay and possesses favorable stability in rat and human 
plasma, which indicates the utility of ML382 as a potential oral dosing regimens (as well as 
intraperitoneal, subcutaneous, or intrathecal). Further use of ML382 in an in vivo animal study 
and the underlying mechanism is reported in following part of the thesis. 
Directly activating MrgprX1 induces itch in rodent and human (Liu et al., 2009; Sikand et 
al., 2011), making it an intractable drug target using traditional orthosteric ligand approach. 
ML382 does not activate MrgprX1 receptor directly and thus does not induce scratching behavior. 
It provided an effective approach to treat chronic pain without inducing itch, which is an 
advantage over the orthosteric agonist BAM peptide. Allosteric modulation is a well-accepted 
concept in the field of drug development in recent years, especially for GPCR targets. For 
example, benzodiazepines are allosteric modulators of γ-aminobutyric acid (GABA)A receptors 
without inducing potential lethal effect by directly activating GABA receptor (Mohler et al., 2002; 
Conn et al., 2009). One of the reasons include that the binding sites across a GPCR subfamily 
are often highly conserved (Conn et al., 2009). Allosteric ligands that bind at allosteric binding site 
provide better specificity since they require the co-localization of receptor and orthosteric ligand to 
function. BAM22 peptide is accumulated at central terminal of sensory neurons during chronic 
pain condition (see model in Fig. 1.1). Thus ML382 could maximize BAM’s effect selectively at 
spinal cord dorsal horn to attenuate the input from MrgprX1+ nerve terminals to inhibit evoked 
persistent and spontaneous pain. Besides, orthosteric ligands can be peptides or proteins that 
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are difficult to pass the brain blood barrier (BBB) when administrated exogenously. Allosteric 
ligands can be designed and screened in small molecule pools and be modified for better drug 
metabolism and pharmacokinetics properties. ML382 was screened in small molecule pools and 
was modified for better potency.   
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CHAPTER 3: THE MOLECULAR MECHANISM OF MRGPRX1 TO INHIBIT 
NEUROTRANSMITTER RELEASE INTO SPINAL CORD DORSAL HORN  
Introduction 
HVA Ca2+ channels play an important role in controlling the release of neurotransmitter 
vesicles from nociceptive DRG neurons into spinal cord neurons (Bao et al., 1998). L-type, P/Q-
type, and N-type HVA Ca2+ channels have been important targets for the development of drugs to 
treat pain (McGivern and McDonough, 2004; Gribkoff, 2006; Perret and Luo, 2009). However, 
because these channels are broadly expressed throughout the peripheral and central nervous 
systems and the cardiovascular system, channel blockers pose side effects such as nausea, 
anxiety, and sweating (Staats et al., 2004; Wermeling, 2005; Klotz, 2006). Many GPCRs, 
including MrgprC11, are known to modulate HVA Ca2+ channels (Chen and Ikeda, 2004; Tedford 
and Zamponi, 2006; Zamponi and Currie, 2013; Li et al., 2014). The most extensively studied 
examples include μ and κ opioid receptors, which mainly inhibit N-type Ca2+ channels and 
mediate reduction of Ca2+-dependent presynaptic neurotransmitter release to produce an 
analgesic effect (Macdonald and Werz, 1986; Tsunoo et al., 1986; Moises et al., 1994; Wiley et 
al., 1997). Since MrgprX1 is more restricted to the pain pathway and can selectively modulate 
HVA Ca2+ channels to attenuate persistent pain, we hypothesized that activating MrgprX1, rather 
than targeting Ca2+ channels directly, can attenuate persistent pain while avoiding most central 
and peripheral side effects. 
The synthetic ligand we used as orthosteric ligand of MrgprX1 was BAM8–22, a 
truncation of BAM with high potency and specificity to MrgprX1 and rodent MrgprCs (Lembo et al., 
2002). The endogenous BAM22 peptide contains the characteristic Met-enkephalin YGGFM motif 
at the N-terminal that activates classic opioid receptor subtypes (μ, δ, κ) (Mizuno et al., 1980). It 
is also a potent ligand for MrgprX1 and MrgprC11 (Mizuno et al., 1980; Han et al., 2002; Lembo 
et al., 2002). Upregulation of BAM22 and MrgprC receptor has been reported in inflammation and 
nerve injury models (Cai et al., 2007; Jiang et al., 2013; He et al., 2014). BAM8–22 has also been 
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reported to inhibit HVA ICa in a previous study using heterologously expressed MrgprX1 in SCG 
and DRG neurons (Chen and Ikeda, 2004). Therefore Mrgprs may represent an endogenous 
inhibitory pathway which parallels that of opioid receptors and converges on BAM peptide to 
neutralize chronic hyperalgesia (Woolf and Salter, 2000; Ji et al., 2003).  
Methods 
All animal experiments were performed under protocols approved by the Animal Care 
and Use Committee of the Johns Hopkins University School of Medicine. 
Generation of MrgprX1 mice  
We purchased a mouse BAC clone (RP23-311C15) containing the entire Mrgpra3 gene 
from the Children’s Hospital Oakland Research Institute. We modified the BAC clone using the 
homologous recombination in bacteria to generate the Mrgprc11Mrgprx1 mouse line. We crossed 
them with Mrgpra3GFP-Cre (Han et al., 2013), and Mrgpr-clusterΔ-/- (Liu et al., 2009) lines that was 
generated in our lab. We used the Mrgprc11Mrgprx1 transgenic line and Mrgpra3GFP-Cre transgenic 
line as hemizygotes or heterozygotes for all the experiments. 
Primary Cell culture  
DRGs from 3–4-week-old mice were collected in cold DH10 medium (DMEM/F-12 with 
10% fetal bovine serum and 1% penicillin/streptomycin, Gibco) and treated with enzyme solution 
(5mg/ml dispase and 1mg/ml collagenase Type I in HBSS without Ca2+ and Mg2+, Gibco) at 37°C. 
After trituration and centrifugation, cells were resuspended in DH10 with nerve growth factor 
(50ng/ml, Upstate) and glial cell line-derived neurotrophic factor (25ng/ml, R&D Systems), plated 
on glass coverslips coated with poly-D-lysine (100 µg/ml, Biomedical Technologies) and laminin 
(10μg/ml, Invitrogen), cultured at 37°C, and used after 20–40 hours (Liu et al., 2009). 
Whole-cell recordings of cultured DRG neurons  
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Whole cell currents of cultured DRG neurons with Mrgpra3-GFP marker were recorded 
with an Axon 700B amplifier and the pCLAMP 9.2 software (Molecular Devices, Sunnyvale, CA, 
USA). Extracellular solution contains (in mM) 130 N-methyl-D-glucamine chloride (NMDG-Cl), 5 
BaCl2, 1 MgCl2, 10 HEPES, and 10 Glucose, with pH of 7.4 adjusted with 1M NMDG. Osmolality 
was adjusted to 310 mOsm/kg with sucrose. Electrodes were pulled (Model pp-830; Narishige, 
East Meadow, NY, USA) from borosilicate glass (WPI, Inc., Sarasota, FL, USA) with resistances 
of 2-4 MΩ. Pipette solution contained 140 Tetraethylammonium chloride (TEA-Cl), 10 EGTA, 1 
MgCl2, 10 HEPES, 0.5 GTP, and 3 ATP, with pH of 7.4 and osmolality about 300 mOsm/kg.  The 
voltage protocol was modified from previous paper (Chen and Ikeda, 2004). Briefly, cells were 
held at -80 mV, evoked to -40 mV for 20 milliseconds (ms) to activate low voltage Ca2+ channels, 
followed by holding to -60 mV for 20 ms, and evoked to -10 mV for 40 ms to activate high voltage 
activated Ca2+ channel. Leak currents were subtracted with P/4 protocol. Liquid junction 
potentials, whole cell capacitances were offset and series resistances were compensated by 70%. 
All experiments were performed at room temperature (21–23 °C). 
Mechanistic study of allosteric modulation 







In this scheme, R is the receptor, A is orthosteric ligand, and B is allosteric modulator. Ka 
and Kb indicate the association constants of ligand O and A, respectively.  When both ligands are 
interacting with the receptor, the two ligands can reciprocally affect the association constants, and 
the magnitude of this cooperativity is determined by the factor α. The equation which describes 











(BX51, Melville, NY, USA). Data were acquired with pClamp 10 software (Molecular Devices) and 
a Multiclamp amplifier. Using a puller (P1000, Sutter, Novato, CA, USA), we fabricated thin-
walled glass pipettes (World Precision Instruments, Sarasota, FL, USA) that had a resistance of 
3-6 MX and were filled with internal solution (in mM: 120 K-gluconate, 20 KCl, 2 MgCl2, 0.5 EGTA, 
2 Na2-ATP, 0.5 Na2-GTP, and 20 HEPES). The cells were voltage clamped at –70 mV. 
Membrane current signals were sampled at 10 kHz and low-pass filtered at 2 kHz. Larger-bore 
pipettes filled with Krebs solution were used for dorsal root stimulation. To evoke EPSCs, we 
delivered paired pulse test stimulation to dorsal root consisting of 2 synaptic volleys (500 μA, 0.1 
ms) 400 ms apart at a frequency of 0.05 Hz to activate high-threshold afferent fibers (C-fibers), 
followed by a 0.1-ms 5-mV depolarizing pulse (to measure R series and R input). We monitored 
R series and R input and discarded cells if either of these values changed by more than 20%. 
The amplitudes of the first (P1) and the second (P2) EPSC were measured and the paired pulse 
ratio (PPR) was calculated as PPR = P2/P1. 
Immunofluorescence  
For spinal cord staining, adult mice (8–12 weeks old) were anesthetized with 
pentobarbital and perfused intracardially with 20 ml 0.1 M PBS (pH 7.4, 4 °C) followed with 25 ml 
of fixative (4% formaldehyde (vol/vol), 4 °C), as previously described (Han et al., 2013). Spinal 
cord was dissected from the perfused mice and post-fixed in fixative at 4 °C for 1 h. Then tissues 
were cryoprotected in 20% sucrose (wt/vol) for 24 h at 4 °C and were sectioned with Vibratome 
cryostat (Polysciences, Warrington, PA). The sections on slides were dried at 37 °C for 15 min, 
and fixed with 4% paraformaldehyde at room temperature for 10 min. Tyramide Signal 
Amplification (TSA) Systems (PerkinElmer, Waltham, MA) was used following the protocol 
provided. Rabbit polyclonal anti-BAM22 antiserum (1:500, ATSBIO, San Diego, CA, USA) in 
1×TNB overnight at 4 °C followed by washing and incubation with secondary HRP-conjugated 
goat anti-rabbit IgG (1:500 in 1×TNB, Vector Laboratories, Burlingame, CA, USA) for 1 h. TSA 




Data are presented as mean ± s.e.m. The number of mice analyzed is represented as n. 
Statistical comparisons were conducted by two-tailed, unpaired or paired Student’s t test 
according to experimental design. Statistical significant difference was assumed at P < 0.05. 
Experiments were replicated biologically at least three times. 
Results 
Generation of humanized MrgprX1 mice 
To establish a mouse model that resembles human Mrgpr signaling, we generated a 
bacterial artificial chromosome (BAC) transgenic Mrgprx1 mouse line. Many Mrgprs, such as 
mouse Mrgpra3 and Mrgprc11 and human Mrgprx1, are expressed only in subsets of small-
diameter sensory neurons in DRG and trigeminal ganglia (Dong et al., 2001). In such a subset of 
sensory neurons, a certain cohort of ion channels and signal transduction pathways are present 
for Mrgpr to properly relay somatosensory information (Han et al., 2002; Wilson et al., 2011). To 
restrict the expression of Mrgprx1 gene in the Mrgpr-expressing subset, we designed the 
construct so that Mrgprx1 expression would be driven by the Mrgprc11 promoter (Fig. 3.1A) 
because human Mrgprx1 is considered most related to mouse Mrgprc11 based on amino acid 
identity, ligand binding profiles, and expression patterns (Dong et al., 2001; Han et al., 2002; 
Lembo et al., 2002). The Mrgprc11Mrgprx1 transgenic line was mated to the Mrgpra3GFP-Cre 
transgenic line in which the green fluorescent protein (GFP)-Cre fusion protein is driven by 
Mrgpra3 promoter (Han et al., 2013). Because Mrgpra3 and Mrgprc11 are expressed in largely 
overlapping subsets of DRG neurons (Han et al., 2013), we were able to identify the neurons 
expressing MrgprX1 transgene for cellular study by intrinsic GFP fluorescence (Fig. 3.1C). Finally, 
we mated these lines with Mrgpr-clusterΔ-/- mice, which have an 845-kilobase deletion that 
removes 12 endogenous Mrgpr genes (Liu et al., 2009) (e.g., Mrgprc11 and Mrgpra3). The 
resulting Mrgpr-clusterΔ-/-; Mrgprc11Mrgprx1; Mrgpra3GFP-Cre mouse line, which we call the 



































The expression of MrgprX1 receptor does not significantly alleviate hypersensitivity during 
persistent pain condition as revealed by formalin induced second-phase pain (Fig. 3.1D,E) and 




























































































Figure 3.1 Generation of humanized MrgprX1 mouse line. (A) The BAC transgenic line 
expresses human Mrgprx1 driven by mouse MrgprC11 promoter. (B) Mrgprc11Mrgprx1 transgenic 
mice were mated with Mrgpra3GFP-Cre transgenic mice and then crossed into the Mrgpr-clusterΔ-/- 
background. Therefore, the Mrgpra3-GFP+ neurons, which are a small subset of all the DRG 
neurons, express human MrgprX1 but not mouse endogenous Mrgprs. (C) The brightfield image 
shows GFP+ neurons, which were used for electrophysiology experiments. (D) The second phase 
of formalin-induced pain was slightly, but not significantly, lower in humanized MrgprX1 mice than 
in Mrgpr-clusterΔ-/- (Mrgpr KO) mice. (E) The cumulative duration of licking and shaking post 
formalin injection into the hind paw in both phases are similar in the two genotypes. (F) Complete 
Freund's adjuvant (CFA)-induced thermal hypersensitivity was similar in humanized MrgprX1 and 





Activation of MrgprX1 inhibits high-voltage activated Ca2+ channels 
To investigate whether activation of MrgprX1 also inhibits Ca2+ channels, we cultured 
acutely dissociated DRG neurons from humanized MrgprX1 mice and recorded Ca2+ current (ICa) 
in neurons labeled with MrgprA3-driven GFP. Every GFP-expressing neuron that we recorded 
responded to BAM8–22. We used a protocol that enabled us to record both low-voltage-activated 
(LVA) and HVA Ca2+ channels simultaneously, as shown in Fig. 3.2A (Chen and Ikeda, 2004). 
We noticed that in our recordings, all of the Mrgpra3-GFP+ neurons dominantly expressed HVA 
Ca2+ channel, very few LVA Ca2+ channel (Fig. 3.2A) (LVA ICa = -20.17 pA ± 2.57 pA , N = 35). 
We found that BAM8–22 inhibited HVA ICa and that ML382 significantly enhanced this inhibition 
(Fig. 3.2A). The inhibition by BAM8–22 was rapid and reversible (Fig. 3.2B). ML382 significantly 
increased inhibition of ICa by 0.5 μM BAM8–22. However, if the concentration of BAM8–22 was 
saturating (5 μM), ML382 was not able to further reduce ICa (Fig. 3.2A,C). The current inhibition 
was voltage-dependent. BAM8–22 shifted voltage dependency of the activation curve to more 
positive membrane potentials, which resulted in reduction of the channel open probability (Fig. 
3.2D). ML382 shifted the activation curve even more in the positive direction in the presence of 
sub-saturating but not saturating concentrations of BAM8–22 (Fig. 3.2D). In the absence of 
BAM8–22, ML382 did not inhibit ICa (Fig. 3.2E) or shift the voltage dependency (Fig. 3.2F). The 
fact that ML382 enhanced BAM8–22 effect but did not act on MrgprX1 per se suggested that 




















Figure 3.2 MrgprX1 induces inhibition of ICa. (A) A representative trace shows the protocol 
used to record current from low- and high-voltage-activated (LVA and HVA) Ca2+ channels. HVA 
ICa was inhibited by BAM8–22 (BAM) and significantly enhanced by ML382. ML382 alone did not 
inhibit HVA ICa. (B) A representative time course of the agonist effects on HVA ICa shows that the 
inhibition is rapid and reversible. (C) Current-voltage relation showing the inhibitory effect of 
BAM8–22 and ML382. (D) Open probability showing that BAM8–22 shifted the voltage 
dependency of the activation curve to more positive membrane potentials. ML382 alone did not 













ML382 is a strong and selective positive allosteric modulator of MrgprX1 
 To confirm that ML382 modulates BAM8–22 binding affinity, we measured dose-
response curves of BAM8–22 in the presence of different concentrations of ML382 in cultured 
DRG neurons from humanized MrgprX1 mice (see example trace without ML382 in Fig. 3.3A). In 
the absence of ML382, the EC50 for BAM8–22 inhibition of ICa was 0.66 ± 0.05 μM. In the 
presence of 0.1, 1, 10, and 30 μM ML382, BAM8–22 EC50 was reduced to 0.43 ± 0.02, 0.25 ± 
0.02, 0.06 ± 0.01, and 0.08 ± 0.01 μM, respectively (Fig. 3.3B). A lower EC50 indicates higher 
binding affinity. This finding that ML382 dose-dependently increases BAM8–22 affinity 
demonstrates that ML382 is a positive allosteric modulator of MrgprX1. To quantify the potency of 
ML382, we applied a ternary complex model developed by De Lean et al. (De Lean et al., 1980) 
to estimate its cooperativity factor as well as its binding affinity (see METHOD). This model is 
needed to measure the binding affinity of ML382 because ML382 itself does not affect MrgprX1. 
Titrating ML382 in the presence of a sub-saturating concentration BAM8–22 is simplistic because 
ML382 affinity would change under the influence of BAM8–22 concentration when these two 
molecules exhibit allostery. In addition, the ternary complex model provides a factor known as α, 
which can be used as an indicator to quantify the magnitude of this allosteric regulation. We 
found the EC50 of ML382 to be 3.2 ± 1.7 μM and the α value to be 11.5 ± 1.3. The fact that α was 
much larger than 1 suggests that ML382 is a very potent positive allosteric modulator (Fig. 3.3C). 
We also cultured DRG neurons from wild-type mice that express MrgprA3-promoter–driven GFP 
in order to test the effect of ML382 on MrgprC11, a close mouse Mrgpr member of MrgprX1 that 
can also be activated by BAM peptides. We found that ML382 did not enhance BAM8–22 
inhibition of current (Fig. 3.3D). Together these data suggest that ML382 is a very potent and 













Figure 3.3 Quantification of the potency of ML382 as a positive allosteric agonist. (A) A 
representative time course shows the protocol used to measure the dose-response curve of 
BAM8–22-induced inhibition of HVA ICa. (B) EC50 of BAM8–22 in the presence and absence of 
different concentrations of BAM8–22. (C) Equation used to calculate the EC50 and α value of 








BAM8–22 predominantly inhibits N-type Ca2+ channel in a partially voltage-dependent manner 
and is sensitive to Gi blocker 
DRG neurons express at least three types of HVA Ca2+ channels, namely N-, P/Q-, and 
L-type (Fox et al., 1987; Yusaf et al., 2001). Each can be isolated by a specific blocker (Catterall, 
2000; Gribkoff, 2006). We found that all three types of calcium channels are present in Mrgpra3-
GFP–labeled neurons (Fig. 3.4A,B). To identify which calcium channel is the downstream target 
of MrgprX1, we used ω-conotoxin GVIA, ω-agatoxin, and nimodipine to block N-type, P/Q-type, 
and L-type HVA Ca2+ channels, respectively. We applied each blocker individually and tested 
BAM8–22-induced current inhibition. Application of 1 μM ω-conotoxin GVIA decreased BAM8–
22-induced inhibition from 52.2% to 10.0%, suggesting that the N-type calcium channel is a major 
target of MrgprX1 (Fig. 3.4C,F). In contrast, 0.5 μM ω-agatoxin and 10 μM nimodipine altered the 
effect of BAM8–22 to 43.5% and 57.4%, respectively (Fig. 3.4D–F). ML382 was not able to divert 
the downstream effect by acting at another HVA when N-type HVA was blocked by ω-conotoxin 


























Figure 3.4 MrgprX1 predominantly inhibits N-type HVA Ca2+ channel. (A) A representative 
trace shows the different components of high-voltage-activated (HVA) ICa separated by blockers.  
(B) A representative time course of the effect of channel blockers on HVA ICa shows that the 
inhibition is rapid and steady. (C) A graph of the current-voltage relationship shows that ω-
conotoxin GVIA (GVIA for short in figures) abolished 90% of BAM8–22-induced current inhibition 
(n = 7 neurons). ML382 did not divert the downstream effect by acting at another HVA channel. 
(D–E) Current-voltage relationship graphs also show that ω-agatoxin TK (TK for short in figures) 
abolished 40% of BAM8–22-induced current inhibition (n = 6 neurons, D) and that nimodipine 
abolished 50% of BAM8–22-induced current inhibition (n = 5 neurons, E). (F) Amplitude of 
BAM8–22-induced current inhibition in the presence of different Ca2+ channel blockers, 
normalized by baseline level of HVA ICa in the same neuron without blockers or BAM8–22. ***P < 




G-protein-mediated inhibition of N-type calcium channels is often coupled to the pertussis 
toxin (PTX)-sensitive Gi/o pathway (Chen and Ikeda, 2004; Raingo et al., 2007) and involves Gβγ 
binding to the intracellular loop in a voltage-dependent manner (Hille et al., 1995; Herlitze et al., 
1996; Qin et al., 1997). To further identify downstream G-protein pathways, we used PTX, 
cholera toxin (CTX), and U73122 to differentiate three types of G-protein signaling, namely Gi/o, 
Gs, and Gq/11-phospholipase C. We found that pretreatment with 2 μg/mL PTX completely 
abolished BAM8–22-induced inhibition (from 50.2% to 1.5%; Fig. 3.5A, D). In contrast, 
pretreatment with 2 μg/mL CTX or 5 μg/mL U73122 reduced BAM8–22-induced inhibition to only 
49.8% and 34.3%, respectively (Fig. 3.5B–D). To investigate the role of Gβγ binding, we 
examined the effect of BAM8–22 with a sandwich protocol, a pair of activation pulses with a 
strong depolarizing intermediate pulse (Fig. 3.5E) (Herlitze et al., 1996; Raingo et al., 2007). If the 
effect of BAM8–22 is mediated by Gβγ binding, the strong depolarizing prepulse will dessociate 
Gβγ from N-type calcium channel and reverse the inhibition. We found that the strong 
depolarizing prepulse reversed 50% of BAM8–22-induced inhibition (Fig. 3.5F). The voltage 
dependent activation curve (PV curve) showed that this voltage protocol fully reversed the voltage 
dependence of the channel (Fig. 3.5G); therefore the remaining inhibition was voltage-
independent. These results confirmed that the analgesic effect of BAM8–22 is mediated by Gi/o-
sensitive Gβγ binding of N-type calcium channel and also suggested the existence of a Gβγ-
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Figure 3.5 MrgprX1 mediates Gi/o-sensitive Gβγ binding to N-type calcium channel. (A) 
Overnight pretreatment of neurons with pertussis toxin (PTX) completely abolished BAM8–22-
induced current inhibition (n = 6 neurons). (B) Overnight pretreatment with cholera toxin (CTX) 
did not produce a notable effect on BAM8–22-induced inhibition (n = 5 neurons). (C) Acute 
perfusion with U73122 (3 minutes) did not produce a notable effect on BAM8–22-induced 
inhibition (n = 5 neurons). (D) Amplitude of BAM8–22-induced inhibition in the absence (control) 
and presence of different blockers, normalized by pre-BAM8–22 baseline of the same neuron. 
Only the PTX-treated group showed a significant decrease compared to control. **P < 0.01 vs 
control. (E) A representative trace shows the sandwich protocol used to relieve Gβγ binding to 
the HVA Ca2+ channels. (F) A graph of the current-voltage relationship shows that the 
depolarizing prepulse reversed 50% of BAM8–22-induced inhibition (n = 6 neurons). (G) Open 
probability shows that the depolarizing prepulse fully reversed the voltage dependence of the 
channel. (H) A schematic model of MrgprX1-mediated HVA ICa inhibition. BAM8–22 activates 
MrgprX1, which predominantly inhibits N-type calcium channels and reduces neurotransmitter 
release. This inhibition is contributed to in part by Gβγ binding. Gαi/o might also be involved. 
ML382 is a selective MrgprX1 allosteric agonist that can boost BAM8–22-induced current 




BAM22 peptide at spinal cord dorsal horn is upregulated during persistent pain conditions 
We next investigated whether endogenous BAM peptides are secreted at the central 
terminal as a physiological mechanism to counteract persistent pain. We stained for BAM22 
peptide immunoreactivity using anti-BAM22 antibody and compared the injured and uninjured 
sides of spinal cord dorsal horn (L4-L5) from humanized MrgprX1 mice 2 days after injection with 
complete Freund's adjuvant (CFA) or 3 weeks after chronic constriction injury (CCI) of the sciatic 
nerve. BAM22 immunoreactivity appeared at superficial layers (laminae I–II) (Chen et al., 2008) 
and was elevated on the injured side (Fig. 3.6A-B). The antibody was validated by pre-absorbed 
the anti-BAM22 antiserum with 10–6 M BAM22, resulting in the complete absence of BAM22 















Figure 3.6 BAM22 immunoreactivity increases during chronic pain condition at spinal cord 
dorsal horn. (A) Representative staining of L4-L5 spinal cord dorsal horn from naïve mice and 
mice subjected to complete Freund's adjuvant (CFA) or chronic constriction injury (CCI). (B) 
Quantification of BAM22 immunoreactivity. *P < 0.05 vs naïve, repeated in5 animals for each 
condition. (C) The anti-BAM22 antiserum was pre-absorbed with 10–6 M BAM22, resulting in the 
absence of BAM22 signal. (D) A continuous section of the spinal cord form the same animal was 
stained with anti-BAM22 antibody that was not pre-absorbed. The BAM22 immunoreactivity was 
seen on the superficial layers of dorsal horn. The right side has a higher level of signal, which 
was ipsilateral to the CFA treatment on the hind paw. Scale bar represents 500 μm.  
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We then quantified the level of BAM22 in mouse spinal cords by a highly sensitive 
targeted mass spectrometry (MS) approach, termed liquid chromatography-selected reaction 
monitoring (LC-SRM). Basically, the BAM22 peptide together with other molecules were extracted 
from the spinal cords, trypsinized, and resolved by reverse phase LC. The eluted BAM22 8-19 
peptide (i.e. VGRPEWWMDYQK) was ionized and transferred into MS that was operated in a 
mode of selected reaction monitoring (SRM). In SRM, the BAM22 peptide ion was separated from 
other co-eluting ions, and then fragmented to generate specific product ions, which indicated the 
intensity of BAM22 in the original samples.  In such a targeted analysis, we first defined the 
precursor ion and fragmented MS/MS pattern of the BAM22 8-19 peptide using a synthetic peptide 
(Fig. 3.7A), then measured the absolute level of BAM22 peptide in CFA treated spinal cord (247 ± 
2 femtomoles per spinal cord, 6.8 nM, Fig. 3.7B). Whereas BAM22 was quantified by three 
different product ions, the specificity of this analysis was strongly supported by identical features 
between the endogenous BAM22-derived peptide and its synthetic counterpart, with respect to 
precursor ion, LC retention time, and multiple product ions. Finally, based on five product ions, we 
found that CFA treatment induced an increase (46.0 ± 3.6 %) of the BAM22 level in the spinal 






Figure 3.7 Quantification of BAM22 peptide in mouse spinal cords by mass spectrometry. 
(A) The MS/MS spectrum of triply charged BAM22 8-19 tryptic peptide (VGRPEWWMDYQK, 532.3 
m/z). (B) Absolute quantitative analysis of BAM22 8-19 (6.8 nM) in the CFA treated mouse spinal 
cord by LC-SRM, based on peak area difference in the CFA-treated spinal cord samples before 
and after adding 250 femtomoles of synthetic BAM22. Three product ions were monitored. In 
addition, the run-to-run variation was corrected by spiking in 100 femtomoles of another synthetic 
peptide (TLSDYNIQKESTLHLVLR, triply charged precursor ion of 710.8 m/z) as external 
standard. (C) Comparison of the BAM22 expression level between control and CFA treated 
mouse spinal cords shows that CFA treatment induced an increase (46.0 ± 3.6 %) of the BAM22 




Activation of MrgprX1 blocks presynaptic functions in the spinal cord dorsal horn  
Because the central projections of Mrgpr+ C-fibers terminate in superficial dorsal horn 
(Han et al., 2013; He et al., 2014), we continued testing whether MrgprX1 acts at central 
terminals by recording from substantia gelatinosa (SG) neurons (lamina II) in lumbar spinal cord 
slices (L4-L5 segments) from mice with CFA-induced inflammation of the hind paw. Evoked 
excitatory presynaptic currents (eEPSCs) were recorded after the application of high-intensity 
paired-pulse stimulation (500 μA, 0.1 ms, 400 ms apart, 3 tests/min) at the dorsal root, which 
activates high-threshold afferent fibers (C-fibers) (Li et al., 2014). In 10 of 18 SG neurons (55.6%), 
0.5 μM BAM8–22 inhibited eEPSCs. This inhibition was significantly enhanced by ML382 (Fig. 
3.8A,B). In contrast, BAM8–22 was not able to inhibit eEPSCs in the SG neurons from Mrgpr-
clusterΔ-/- mice in the presence or absence of ML382. ML382 alone did not have any effect on SG 
neuron eEPSCs from either humanized MrgprX1 or Mrgpr-clusterΔ-/- mice.  
To examine further whether such inhibition of postsynaptic response involves a decrease 
in presynaptic release of excitatory neurotransmitters, we used a paired pulse test stimulation of 
dorsal root to quantify paired pulse ratio (PPR) in the presence or absence of BAM8–22 or ML382. 
A pair of two synaptic volleys (500 μA, 0.1 ms) was applied at a frequency of 0.05 Hz. The PPR is 
defined as the 2nd eEPSCs (P2) over the the 1st eEPSC (P1) evoked by these two pulse. The 
change in PPR can be used to indicate that the inhibition of postsynaptic response by a drug may 
involve presynaptic inhibition of the release of excitatory neurotransmitters (Heinl et al., 2011; Li 
et al., 2014). We found that 0.5 μM BAM8–22 with 5 μM ML382 increased PPR significantly, 
suggesting presynaptic modulation of eEPSCs. ML382 alone did not affect PPR (Fig. 3.8C,D). 
Importantly, this phenomenon was observed only in slices from humanized MrgprX1 mice, not in 





















































































Figure 3.8 MrgprX1 activation blocks presynaptic functions in spinal cord dorsal horn.  (A) 
Representative trace of evoked EPSCs in the presence of agonists in substantia gelatinosa (SG) 
neurons from CFA-treated humanized MrgprX1 mice and Mrgpr-clusterΔ-/- mice (Mrgpr KO). (B) 
BAM8–22 (0.5 μM) significantly decreased evoked EPSCs of SG neurons (n = 10 neurons). The 
inhibition was enhanced by ML382 (5 μM; n = 10 neurons). ML382 alone did not affect evoked 
EPSCs (n = 7 neurons from humanized MrgprX1 mice, n = 11 neurons from Mrgpr KO mice). 
Neurons from Mrgpr KO mice did not respond to BAM8–22 or ML382 (n = 8 neurons). ***P < 
0.001 vs pre-drug value; ###P < 0.001 vs BAM8–22. (C) Representative traces of evoked EPSCs 
in response to high-intensity, paired-pulse stimulation (500 μA, 0.1 ms, 400 ms interval) before 
(black) and 5 minutes after (red) bath application of BAM8–22 and ML382 in SG neurons from 
CFA-injected humanized MrgprX1 mice and Mrgpr KO mice. (D) In the MrgprX1 group, BAM8–22 
and ML382 increased the paired pulse ratio. *P < 0.05 vs pre-drug baseline. Paired Student’s t-




In summary, our electrophysiology data indicated that ML382 enhanced the ability of 
MrgprX1 to inhibit high-voltage activated Ca2+ channels by increasing the potency of BAM8–22. 
Endogenous MrgprX1 agonist BAM22 is up-regulated at spinal cord dorsal horn under chronic 
pain condition. Activation of MrgprX1 by BAM8–22 reduces neurotransmitter release by inhibiting 
N-type voltage-activated calcium current through PTX sensitive Gi/o pathway. Together, the 
evidence unveils the endogenous negative feedback machinery of MrgprX1 as a target of 
endogenous peptide BAM22 to tune down central sensitization during chronic pain. 
Our electrophysiogical study showed that activation of MrgprX1 inhibits HVA ICa, 
consistent with the results of a previous study that used heterologously expressed MrgprX1 in 
superior cervical ganglion and DRG neurons (Chen and Ikeda, 2004). Interestingly, that study 
showed that MrgprX1 couples to HVA but not LVA (Chen and Ikeda, 2004). Similarly, the 
Mrgpra3-GFP+ neurons that we recorded do not possess an LVA component. This finding 
suggests that the MrgprX1 pathway is highly preserved in a specific subpopulation of peripheral 
neurons. It also supports our experimental design to drive MrgprX1 gene with the mouse 
MrgprC11 in order to restore a physiologically relevant expression pattern.  
We found that MrgprX1 inhibits mainly N-type Ca2+ channels, similar to what we found 
with MrgprC11 activation (Li et al., 2014). N-type HVA Ca2+ channels can bind to the protein 
SNAP-25 and syntaxin-1A and couple the opening of the channels to vesicle fusion, causing 
neurotransmitter release into the spinal cord dorsal horn (Catterall, 2000; Yusaf et al., 2001; 
McGivern and McDonough, 2004; Gribkoff, 2006). N-type HVA channel is also an important 
target for opioid inhibition of pain through the Gi/o pathway (Hescheler et al., 1987; Kaneko et al., 
1994; Moises et al., 1994; Bourinet et al., 1996), indicating again that Mrgprs may be an 
endogenous inhibitory pathway parallel to opioid system. 
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Our electrophysiological study also confirmed that BAM8–22 inhibition of HVA ICa is 
partially voltage-dependent (Chen and Ikeda, 2004). A strong depolarizing pulse reversed 50% of 
the inhibition mediated by BAM8–22. This finding suggests partial involvement of Gβγ binding. 
Unlike Chen and Ikeda (Chen and Ikeda, 2004), we observed that overnight pretreatment with 
PTX completely abolished BAM8–22 inhibition of HVA ICa, suggesting that BAM8–22 activates 
MrgprX1 and triggers Gi/o-sensitive Gβγ binding to N-type calcium channels. The discrepancy 
between our data and theirs suggests that MrgprX1 receptor might activate different G protein 
pathways in different subpopulations of DRG neurons. Therefore we studied MrgprX1 receptor in 
Mrgpra3-GFP+ neurons.  
The inhibition of N-type HVA ICa in DRG neurons caused a decrease in neurotransmitter 
release into spinal cord dorsal horn neurons, as we observed reduced eEPSCs in the presence of 
BAM8–22 and ML382. We confirmed that this effect occurs presynaptically at the central terminal 
of Mrgpra3-GFP+ DRG neurons, as PPR of SG neurons increased. Though Mrgprc promoter is 
expressed in ~10% of mouse DRG neurons, over half of SG neurons in the dorsal horn from 
CFA-treated humanized MrgprX1 mice responded to BAM8–22, suggesting that Mrgpr+ DRG 
central termini form broad branches and arborize extensively in superficial dorsal horn to contact 
multiple postsynaptic neurons (Li et al., 2014). 
ML382 was unable to enhance the inhibition of HVA ICa by BAM8–22 in MrgprC11-
expressing DRG neurons from wild-type animals. MrgprX1 and MrgprC11 exhibit considerable 
difference in drug profile though they share 54% amino acid identity (Han et al., 2002). Species 
differences across Mrgprs are the main reason that many agonists have been reported for 
MrgprX1 but only a few were tested for in vivo functions (Lembo et al., 2002; Sikand et al., 2011; 
Wen et al., 2015). Thus, our humanized MrgprX1 mouse model provides a unique rodent platform 




CHAPTER 4: ML382 INHIBITS PERSISTENT PAIN BEHAVIORALLY 
Introduction 
Nociceptors are the subpopulation of peripheral nerve fibers that detect harmful irritation 
such as intense thermal, mechanical or chemical stimuli (Basbaum and Jessell, 2000). Pain 
sensation is not recognized as a hard wired system, but rather a highly plastic one with the 
engagement of molecules and circuits (Basbaum et al., 2009). The nociceptors peripherally 
innervate the body (DRG neurons) and the face (trigeminal ganglion) and centrally relay 
information into the spinal cord dorsal horn. The nociception information is then ascended 
through spinothalamic tract into the brain (including thalamus, somatosensory cortex, midbrain, 
etc.). Modulation and integration happens at each of the above steps Therefore human sensation 
of pain is plastic and human experience of pain is multidimensional which comprises sensory, 
affective and cognitive aspects (Navratilova et al., 2013). It facilitates not only withdrawal and 
self-guarding from damaging situation but also learning process to avoid similar harmful situation 
in the future (Cox et al., 2010). Though pre-clinical research largely focuses on the molecular and 
cellular mechanism of the sensory aspect of evoked or persistent pain, the other aspects also 
need to be take into consideration during drug development, especially the affective aspect which 
is reported to be the most bothersome to human patients with ongoing persistent pain (Fields, 
1999; Fields, 2007). Though difficult to be measured directly as the pain sensory behaviors in 
nonverbal animals, the affective/aversive aspect has been assessed by pain researchers using 
operant learning behavior. The principle is that the animals are motivated to avoid pain and 
incline to relief from ongoing pain, and thus allows researchers to evaluate avoidance from painful 
situation and reward from the termination of ongoing pain.  
After demonstrating that the MrgprX1 receptor and endogenous orthosteric agonist BAM 
peptide function at the central terminal, we aimed to verify whether the allosteric modulator 
ML382 is able to produce analgesic effect in persistent pain conditions. We evaluated the relief of 




Chronic pain models  
Inflammation was induced by injecting the hind paw of mice subcutaneously with 6 µL of 
50% CFA solution in saline (Guan et al., 2010). Pain response change was evaluated 24–48 
hours after injection. 
Neuropathic pain was induced by CCI of the sciatic nerve as previously described (He et 
al., 2014). Mice were anesthetized by inhalation of 2% isoflurane delivered through a nose cone. 
The left sciatic nerve at the middle thigh level was separated from the surrounding tissue and 
loosely tied with three nylon sutures (9-0 nonabsorbable monofilament, S&T AG, Neuhausen, 
Switzerland). The ligatures were approximately 0.5 mm apart. 
Behavioral studies 
Behavioral assays were performed by experimenters blind to genotype. The mice used in 
the tests were backcrossed to C57Bl/6 mice for at least 10 generations and were 2- to 3-month-
old (20–30 g) males.  
Intrathecal injection was performed as previously described (Guan et al., 2010). Briefly, 
ML382 was dissolved in DMSO to 50 mM, suspended in 0.9% saline to the desired working 
concentration, and injected into the intrathecal space under brief isoflurane (1.5%) anesthesia. A 
30-gauge, 0.5-inch needle connected to a 50-μL syringe was inserted into one side of the L5 or 
L6 spinous process and moved carefully forward to the intervertebral space. A tail flick indicated 
that the tip of the needle was inserted into the subarachnoid space. The needle was removed 
after administration of 10–12 μL of drug solution. 
 One day before the formalin test, mice were acclimated to the environment for 1 hour. On 
the day of test, 7 μL of 2% formalin in saline was injected into the plantar region of one hind paw. 
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Spontaneous pain behavior (licking and twitching) was recorded for 60 minutes (Guan et al., 
2010). 
The Hargreaves test was performed as described in Han et al. (2013). Mice were placed 
under a transparent plastic box (4.5 × 5 × 10 cm) on a glass floor. Infrared light was delivered 
through the glass floor to the hind paw. After acclimatization sessions, the latency for the animal 
to withdraw its hind paw was measured. 
For the conditioned place preference test, humanized MrgprX1 and Mrgpr-clusterΔ-/- mice 
underwent CCI of the left sciatic nerve. On day 7 after CCI, both naïve and nerve-injured animals 
were habituated (30 minutes/day) in an automated 3-chamber box to which they had access to all 
chambers.  The two larger chambers of this apparatus contained distinct visual (vertical stripes vs. 
triangular shapes) and tactile (smooth floor vs. grooved floor texture) cues. The third, smaller 
chamber was interposed between the other two and was devoid of overt spatial cues. On the pre-
conditioning day (day 11 post-CCI), behavior was video recorded for 15 minutes while the mice 
were again free to explore all 3 chambers. The results were used to quantify any basal chamber 
preference or aversion in individual mice. In keeping with a previous study (King et al., 2009), 
animals that spent more than 80% (> 720 seconds) or less than 20% (< 120 seconds) of the total 
time in any given chamber were eliminated from further testing. The next day (day 12 post-CCI), 
animals received a lumbar puncture injection of vehicle (saline, 10–12 µL, i.th.) under anesthesia 
and 10 minutes later were placed in one of the conditioning chambers for 45 minutes. Four hours 
later, the same animals received a lumbar puncture injection of ML382 (250 µM, 10-15 µL) and 
10 minutes later were restricted to the opposite conditioning chamber for 45 minutes. On the 
post-conditioning test day (day 13 post-CCI), animals were placed in the same 3-chamber box 
with access to all chambers but received no injection. Their behavior was recorded for 15 minutes 
and used to analyze chamber preference or aversion.  Data were pooled from 7 groups of mice, 
each containing humanized MrgprX1 and Mrgpr-clusterΔ-/- nerve-injured and naive animals. 
Pairing of ML382 or vehicle with a given chamber was counterbalanced between groups. For 
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each treatment group, we compared time spent in each chamber during pre- and post-
conditioning days by paired t-test to determine if conditioned place aversion or preference was 
present. An increase in post-conditioning time spent in the ML382-paired chamber, as compared 
with pre-conditioning time in the same chamber, indicated conditioned place preference. In 
addition, difference scores were calculated as: (Post-conditioning time – Pre-conditioning time). 
For itch behavioral study, mice had been acclimatized one day before test. BAM8–22 or 
ML382 was injected subcutaneously into the nape of the neck (50 μL), intraperitoneally (100 μL), 
or intrathecally (10-12 μL). Behavioral responses were video recorded for 30 minutes. The video 
recording was subsequently played back in slow motion, and an investigator counted the number 
of bouts of scratching with the hind paw around the injection site.  
For motor function test, we used the rotarod test to evaluate whether central 
administration of ML382 affects motor function as described in Han et al. (2013). All animals were 
brought to the behavior room 10–20 minutes before the test. The mice habituated in the rotarod 
apparatus (Rotamex, Columbus Instruments) at a constant speed of 4 rpm for 10 minutes 3–5 
times on day 1. Then, on day 2, they received three acceleration training sessions separated by 
20 minutes. Speeds increased from 4 rpm to 40 rpm (with a 4.0-rpm increase every 30 seconds). 
On day 3, they received three trials before drug administration (in the same acceleration mode as 
day two). Then ML382 was applied intrathecally without isoflurane. The mice were tested three 
times 30 minutes after drug administration. The end point of the experiment was defined as the 
time at which the mice fell from the apparatus or rolled over the rod by holding onto it. The latency 
to the end point was recorded and analyzed.  
Results 
ML382 inhibits persistent pain in an MrgprX1-dependent manner 
ML382 was applied intrathecally (25 μM, 10 μL) half an hour before formalin (2% 





























Formalin test post-ML382 (i.th., 25µM) 
response (first 10 minutes post-formalin) was not affected, but the inflammatory pain response 
(10 to 60 minutes post-formalin) was significantly attenuated by ML382 in humanized MrgprX1 








Figure 4.1 ML382 attenuates formalin induced second phase pain without exogenous 
BAM8–22. (A) ML382 significantly reduced formalin-induced pain during the second phase. *P < 
0.05. (B) Cumulative duration of paw licking and shaking after formalin injection showed that the 
second phase of pain behavior was significantly reduced in MrgprX1 animals. ***P < 0.0001 vs 
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Mrgpr KO  ML382 (µM) 
We then induced inflammation by intraplantar injection of CFA and quantified heat 
sensitivity with the Hargreaves test. We measured response before and 1 day after CFA injection 
to confirm the development of inflammation. Then, mice were anesthetized with isoflurane and 
injected intrathecally with ML382 (25, 125, or 250 μM in 10 μL). A half hour after recovery from 
isoflurane, response was measured again. We found that ML382 significantly attenuated heat 
sensitivity in humanized MrgprX1 mice but not in Mrgpr-clusterΔ-/- mice (Fig. 4.2A,B). 














Figure 4.2 CFA induced persistent inflammatory pain was attenuated by ML382. (A) 
Complete Freund's adjuvant (CFA)-induced heat hypersensitivity of the ipsilateral hind paw was 
dose-dependently attenuated by ML382. Paw withdrawal latency measured with the Hargreaves 
test. *P < 0.05, **P <0.01 vs pre-ML382 baseline. (B) ML382 was not effective in Mrgpr KO mice. 
Contralateral heat sensation was not altered by CFA injection or ML382 in either MrgprX1 (C) or 











































































































































































MrgprX1  ML382 (µM) 
We also performed CCI to induce neuropathic pain and quantified heat sensitivity with the 
Hargreaves test. We measured response before and 2 weeks after surgery to confirm the 
development of neuropathic pain. Again we found that ML382 significantly attenuated heat 
sensitivity in humanized MrgprX1 mice but not in Mrgpr-clusterΔ-/- mice (Fig. 4.3A,B). 














Figure 4.3 CCI induced persistent neuropathic pain was attenuated by ML382. (A) Chronic 
constriction injury (CCI)-induced heat hypersensitivity of the ipsilateral hind paw was dose-
dependently attenuated by ML382. **P < 0.01, ***P < 0.001 vs pre-ML382 baseline. (B) ML382 
was not effective in Mrgpr KO mice. Contralateral heat sensation was not altered by CCI or 














ML382 induces conditioned place preference selectively in nerve-injured humanized MrgprX1 
mice 
Clinically, spontaneous pain is a debilitating aspect of neuropathic pain caused by 
neuropathic spontaneous discharge in somatosensory neurons (Bennett, 2012). It can be studied 
in rodents with a conditioned preference paradigm, which can unveil the rewarding effect of pain 
relief (King et al., 2009). In humanized MrgprX1 mice that had undergone CCI, lumbar puncture 
injection of ML382 (250 µM, 10-12 µL) led to a significant increase in post-conditioning time spent 
in an ML382-paired chamber, as compared to the pre-conditioning value (Fig. 4.4A). 
Simultaneously, the mice decreased time spent in the vehicle (saline)-paired chamber (Fig. 4.4A). 
However, Mrgpr-clusterΔ-/- mice showed no significant change in post-conditioning time spent in 
the ML382- or vehicle-paired chamber, as compared to the respective pre-conditioning values 
(Fig. 4.4A). The difference score (Post-conditioning time – Pre-conditioning time) confirmed that 
only MrgprX1 mice showed a preference for the ML382-paired chamber (Fig. 4.4B). Mrgpr-
clusterΔ-/- mice showed neither preference nor aversion to ML382 treatment (Fig. 4.4A,B). These 
results suggest that allosteric modulator ML382 is sufficient to alleviate ongoing pain in 
humanized MrgprX1 mice with endogenous BAM peptides as orthosteric ligand. The amount of 
endogenous BAM peptide in the dorsal spinal cord involved is sufficiently (as is supported by 
HPLC data in Fig. 3.7). Importantly, ML382 did not induce conditioned place preference in naïve 
animals, suggesting that induction occurs solely by relief from ongoing pain and that the drug 
itself is not rewarding (Fig. 4.4C,D). Clonidine was used in CCI neuropathic pain animal model as 
positive control compound for CPP, and clonidine in naïve animals as negative control for CPP. 
The results showed that clonidine successfully induced CPP in injured animals regardless of 
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Figure 4.4 ML382 induces conditioned place preference in MrgprX1 animals without 
exogenous BAM8–22. (A) MrgprX1 and Mrgpr KO mice were subjected to chronic constriction 
injury (CCI) of the sciatic nerve. MrgprX1 mice spent significantly more time in the ML382-paired 
chamber and less time in the saline-paired chamber compared to times at pre-conditioning 
baseline. Mrgpr KO mice did not develop preference for or aversion to the ML382-paired chamber. 
*P < 0.05, **P < 0.01 vs pre-conditioning baseline. (B) The difference score confirmed that only 
MrgprX1 mice showed preference for the ML382-paired chamber. **P < 0.01 vs saline-paired 
chamber. Statistical power is 0.978 in MrgprX1 animals. (C) In the uninjured, naïve condition, 
neither MrgprX1 nor Mrgpr KO mice developed preference for or aversion to the ML382-paired 
chamber. (D) This finding was confirmed by the difference score. Two-factor repeated ANOVA, 
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Figure 4.5 Positive control of conditioned place reference induced by clonidine. (A) 
Intrathecally delivered clonidine (1 µg dissolved in 5 µL saline) induced chamber preference in 
CCI mice, regardless of genotypes. * P < 0.05 vs preconditioning baseline. (B) The difference 
score confirmed that both genotypes showed preference for the clonidine-paired chamber. *P < 
0.05 vs saline-paired chamber. Statistical power is 0.700 in MrgprX1 animals and 0.620 in Mrgpr 
KO animals. (C) Same dose of clonidine did not induce chamber preference in naïve mice, 
regardless of genotypes. (D) The difference score confirmed that neither genotypes showed 
preference for the clonidine-paired chamber. Two-factor repeated ANOVA, Bonferroni post hoc 



























ML382 does not induce scratching behavior or impair motor function 
Besides inhibiting pain, Mrgprs also function as itch receptors in the peripheral terminals. 
BAM8–22 inhibits pain but also induces scratching behavior when injected subcutaneously (Fig. 
4.6A) (Liu et al., 2009; Sikand et al., 2011; Han et al., 2013). We scored mice for scratching 
behavior after ML382 was applied subcutaneously into the back, intraperitoneally, or intrathecally. 
We did not observe a significant difference between the humanized MrgprX1 group and Mrgpr-
clusterΔ-/- group, indicating that ML382 does not induce itch (Fig. 4.6A). Moreover, ML382 (250 








Figure 4.6 ML382 did not induce scratching behavior or impair motor function. (A) ML382 
did not induce scratching behavior when applied subcutaneously (s.c.) into the back, 
intraperitoneally (i.p.), or intrathecally (i.th.) in humanized MrgprX1 mice. Subcutaneous injection 
of BAM8–22 caused rigorous scratching behavior. n = 5-7 for each treatment. N.S. stands for not 
statistically significant. (B) Naïve (uninjured) humanized MrgprX1 mice and Mrgpr-clusterΔ-/- mice 
did not differ in motor function as measured by rotarod test. Neither group was affected after an 











































Our study also revealed that ML382 produced conditioned place preference to the relief 
of CCI-induced ongoing neuropathic pain. Operant behavior studies such as the conditioned 
place test measure the affective/aversive aspect of spontaneous pain experience, which relates 
closely to the complex human experience of chronic pain (Navratilova et al., 2013). One example 
involves spinal administration of adenosine, which blocked evoked hyperalgesia in patients with 
neuropathic pain but failed to alleviate overall ongoing pain (Eisenach et al., 2003). Intrathecal 
administration of adenosine in the rat model of spinal nerve ligation-induced neuropathic pain 
revealed that adenosine reversed tactile hypersensitivity but failed to produce conditioned place 
preference (King et al., 2009). Therefore, this operant behavior study is of high translational 
relevance and indicates that ML382 is a promising anti-pain compound. Furthermore, ML382 was 
not rewarding in naïve animals. This feature is important because it suggests a low likelihood for 
abuse. 
One limitation of ML382 is that it is not effective in inhibiting mechanical allodynia induced 
by CFA injection in the hind paw or sciatic nerve CCI as detected by von Frey fiber (data not 
shown). A possible explanation is that ML382 is allosteric modulator that can maximize but not 
surpass the effect of the orthosteric agonist BAM8–22. According to Jiang et al. (Jiang et al., 
2013), BAM8–22 (i.th. 30nmol) did not change CFA-induced mechanical hypersensitivity of male 
Sprague-Dawley rats. Therefore ML382 might also be limited in its ability to inhibit mechanical 
allodynia through Mrgpr pathway. However, BAM8–22 (i.th. 1 mM, 5 µL) was reported to 
attenuate mechanical allodynia (assessed by von Frey fiber) as well as thermal hyperalgesia 
(assessed by Hargreaves test) of persistent inflammatory (induced by intraplantar CFA injection) 
and neuropathic pain (induced by sciatic nerve CCI) in wild type C57BL/6 mice (Guan et al., 
2010). MrgprC selective agonist JHU58 (i.th. 0.5 mM, 5 µL), a peptidomimetic of Arg-Phe-NH2, 
was also reported to inhibit attenuate both mechanical allodynia and thermal hyperalgesia in 
MrgprC dependent manner (He et al., 2014). Therefore, mouse MrgprC11, rat MrgprC and 
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human MrgprX1 might differ in their downstream effect of fine tuning thermal hyperalgesia or 
mechanical allodynia. It is notable that BAM8–22 and JHU58 at their antinociceptive dose induce 
mild irritation (e.g., scratching and tail-flicking) in wild type and KO animals (Guan et al., 2010; He 
et al., 2014), which was not observed in the case of ML382. This suggested that MrgprC agonists 
possess nonselective action in an MrgprC independent manner or they function through Mrgpr 
family members that are not one of the twelve deleted Mrgpr cluster (He et al., 2014). Allosteric 
modulation requires the presence of both the receptor and orthosteric agonist, therefore can 
avoid potential nonselective/off-target action where another closely related Mrgpr member is 




CHAPTER 5: CONCLUSION AND FUTURE DIRECTIONS 
A major goal of this thesis is to develop a pain-selective pharmacological intervention that 
targets at nociceptive sensory neurons at periphery. Accordingly, we screened small molecular 
compounds targeting at human MrgprX1 receptor. Mrgprs are a family of orphan G-protein-
coupled receptors (GPCRs) consisting of many genes in human, rat, and mouse (Dong et al., 
2001; Lembo et al., 2002; Choi and Lahn, 2003; Zhang et al., 2005; Gloriam et al., 2007). 
Previous work has implicated that many Mrgprs, including human MrgprX1, are expressed 
specifically in small-diameter afferent neurons (presumably nociceptive) and have been reported 
to play important roles in somatosensation of pain and itch (Zylka et al., 2003; Conn et al., 2009; 
Liu et al., 2009; Guan et al., 2010; Sikand et al., 2011; Liu et al., 2012; Han et al., 2013; He et al., 
2014; He et al., 2014). Using calcium mobilization functional assays in HEK293 heterologous 
system stably express MrgprX1, we found that some drug candidates act on MrgprX1 as 
allosteric modulators at the presence of BAM8–22 as the orthosteric agonist. Allosteric 
modulators often can offer proper temporal and spatial control of endogenous physiological 
signaling because of the requirement for the presence of endogenous orthosteric ligand. To 
confirm the in vivo function, we established a transgenic mouse line in which human MrgprX1 
gene is expressed in Mrgpr-expressing primary sensory DRG neurons. This valuable humanized 
mouse line allowed us to do animals tests because the mouse Mrgprs are not responsive to many 
MrgprX1 agonists or modulators including ML382. Using electrophysiology study on neuronal 
culture, we found that ML382 enhanced the ability of MrgprX1 to inhibit N-type channels and 
block presynaptic terminal function. Immunostaining results and HPLC analysis also implicated 
an increase amount of endogenous BAM peptide at injury condition. Based on the above findings 
we next performed behavioral study and evaluated the analgesic effect of ML382. We showed 
that ML382 also effectively attenuated evoked persistent pain and spontaneous pain in vivo, 
without causing central or peripheral side effects such as itch. 
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ML382 is a promising anti-pain compound since it can inhibit neuropathic pain in both 
sensory dimension and affective dimension, and may have good effectiveness in patients with 
ongoing spontaneous neuropathic pain. Furthermore, ML382 induced CPP was not observed in 
naïve animals, suggesting it relieved ongoing pain instead of being rewarding itself. Interestingly, 
we were only able to observe analgesic effect when ML382 is given i.th. but not i.p. or 
subcutaneously (data not shown). Further modification of the structure of ML382 is in progress, 
aiming to improve the penetration ability across blood brain barrier to reach central terminals of 
primary sensory neurons in the spinal cord so that it could be administrated systemically instead 
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